Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 1,001–1,029 of 1,029
Ubiquitin-proteasome system in diabetic retinopathy
Svikle, Z., Pēterfelde, B., Sjakste, N., Baumane, K., Verkauskienė, R., Jeng, C., & Sokolovska, J. (2022) · PeerJ · doi:10.7717/peerj.13715 · Cited by 40
Giloyan, A., Harutyunyan, T., & Petrosyan, V. (2015) · BMC Ophthalmology · doi:10.1186/s12886-015-0032-0 · Cited by 36
“6% [36], while the study by Ruta et al.”
BackgroundPrimary prevention of diabetic retinopathy with fibrates: A retrospective, matched cohort study
Morgan, C. L., Owens, D. R., Aubonnet, P., Carr, E. S. M., Jenkins-Jones, S., Poole, C. D., & Currie, C. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-004025 · Cited by 31
Zhang, B., Wang, Q., Zhang, X., Jiang, L., Li, L., & Liu, B. (2021) · BMC Ophthalmology · doi:10.1186/s12886-021-01883-w · Cited by 30
“[3] Thus, dealing with DR is an urgent need for the global health system.”
BackgroundSelf-citation(2022) · doi:10.1186/s12909-022-03272-3 · Cited by 30
“Introduction Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of irreversible vision loss in working-age adults [1].”
BackgroundInvestigating factors associated with depression of type 2 diabetic retinopathy patients in China
Xu, X., Zhao, X., Qian, D., Dong, Q., & Gu, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132616 · Cited by 29
“Longer diabetes duration and poorer blood glucose management are strongly associated with DR[2].”
BackgroundHe, F., Ng Yin Ling, C., Nusinovici, S., Cheng, C.-Y., Wong, T. Y., Li, J., & Sabanayagam, C. (2024) · Journal of Medical Internet Research · doi:10.2196/41065 · Cited by 29
“Among these, diabetic kidney disease (DKD) was estimated to develop in around 40% of the population with diabetes [3], while diabetic retinopathy (DR) would manifest in approximately 35% [4].”
Self-citationMuqit, M. M. K., Kourgialis, N., Jackson-deGraffenried, M., Talukder, Z., Khetran, E. R., Rahman, A., Chan, W. O., Chowdury, F. A., Nag, D., Ahmad, J., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16285 · Cited by 28
Li, H., Li, G., Li, N., Liu, C., Yuan, Z., Gao, Q., Hao, S., Fan, S., & Yang, J. (2023) · PLOS ONE · doi:10.1371/journal.pone.0291390 · Cited by 27
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
“Because there are already effective and safe therapies for neovascular AMD, DR, and DME based on inhibition of VEGF, this approach to endogenously express and produce these therapeutic molecules in the eye is most promising.”
BackgroundInfluentialSelf-citationBegum, T., Rahman, A., Nomani, D., Mamun, A., Adams, A., Islam, S., Khair, Z., Khair, Z., & Anwar, I. (2021) · JMIR Public Health and Surveillance · doi:10.2196/23538 · Cited by 24
Mehra, A. A., Softing, A., Guner, M. K., Hodge, D. O., & Barkmeier, A. J. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.08.008 · Cited by 24
Amelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein–Coupled Receptor 5
Cai, Z., Yuan, S., Zhong, Y., Deng, L., Li, J., Tan, X., & Feng, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.637051 · Cited by 23
“Macrovascular and microvascular complications related to DM, such as coronary heart disease, stroke, peripheral arterial disease, diabetic retinopathy (DR), and kidney disease (Adler et al., 2003; Yau et al., 2012; Einarson et al., 2018), represent the main health burdens in patients with DM.”
BackgroundDiabetic retinopathy screening in persons with mental illness: a literature review
Bradley, E. R., & Delaffon, V. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000437 · Cited by 22
Wadhwani, M., Vashist, P., Singh, S. S., Gupta, N., Malhotra, S., Gupta, A., Shukla, P., Bhardwaj, A., & Gupta, V. (2018) · Tropical Medicine & International Health · doi:10.1111/tmi.13039 · Cited by 22
“2% of all diabetics have vision-threatening DR [4].”
BackgroundMicrovascular disease increases the risk of lower limb amputation – A Western Danish cohort study
Olesen, K. K. W., Anand, S., Thim, T., Gyldenkerne, C., & Maeng, M. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13812 · Cited by 21
Tsai, M.-J., Hsieh, Y.-T., Tsai, C.-H., Chen, M., Hsieh, A.-T., Tsai, C.-W., & Chen, M.-L. (2022) · Journal of Diabetes Research · doi:10.1155/2022/5779276 · Cited by 18
Development and Validation of a Diabetic Retinopathy Risk Stratification Algorithm
Tarasewicz, D., Karter, A. J., Pimentel, N., Moffet, H. H., Thai, K. K., Schlessinger, D., Sofrygin, O., & Melles, R. B. (2023) · Diabetes Care · doi:10.2337/dc22-1168 · Cited by 17
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025) · Eye · doi:10.1038/s41433-024-03529-9 · Cited by 14
“Macular fluid accumulates in diabetic eye disease (diabetic macular oedema [DMO]) and retinal vein occlusions (RVO) that includes both central retinal vein occlusion (CRVO) and branch retinal vein occlusions (BRVO)—the three common retinal vascular diseases that cause visual impairment [1, 2].”
Wolf, R. M., Channa, R., Lehmann, H. P., Abramoff, M. D., & Liu, T. Y. A. (2024) · Clinical Diabetes · doi:10.2337/cd23-0019 · Cited by 12
Tóth, G., Limburg, H., Szabó, D., Sándor, G. L., Nagy, Z. Z., & Németh, J. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316337 · Cited by 11
Bhambhwani, V., Whitestone, N., Patnaik, J. L., Ojeda, A., Scali, J., & Cherwek, D. H. (2025) · Ophthalmic Epidemiology · doi:10.1080/09286586.2024.2434738 · Cited by 11
Interventions to increase attendance for diabetic retinopathy screening
Lawrenson, J. G., Graham-Rowe, E., Lorencatto, F., Presseau, J., Burr, J., Ivers, N., Quartilho, A., Bunce, C., Francis, J. J., Grimshaw, J. M., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012054 · Cited by 10
Chantzichristos, D., Persson, A., Miftaraj, M., Eliasson, B., Svensson, A.-M., & Johannsson, G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02064 · Cited by 9
Sun, W., Su, M., Zhuang, L., Ding, Y., Zhang, Q., & Lyu, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-66157-z · Cited by 8
Leigh, J., Drinkwater, J., Turner, A., & Schroeder, E. (2026) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.70016 · Cited by 8
Leong, A., Wolf, R. M., Channa, R., Wang, J., Lehmann, H., Abramoff, M. D., & Liu, T. Y. A. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02460-5 · Cited by 7
Self-citationLeigh, J. A., Sherrington, A., Barber, A. R. J., Turner, A. W., Kidd, M., Powell, J., & Pope, C. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02616-3 · Cited by 3
Di Matteo, L., Whitestone, N., & Bhambhwani, V. (2026) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2026-002904 · Cited by 1
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.